A new study in the journal JAMA Pediatrics found that less than 0.1% of adolescents in the U.S. were prescribed puberty blockers or gender-affirming hormones.

Fewer than 1 in 1,000 U.S. adolescents with commercial insurance received gender-affirming medications — puberty blockers or hormones — during a recent five-year period, according to the study released Monday.

While opponents of gender-affirming care for trans youth often act as if such care is common and undertaken thoughtlessly, it’s actually quite rare, according to a new study. The study, published Monday in JAMA Pediatrics,

From 2018 through 2022, only 926 adolescents with a gender-related diagnosis received puberty blockers and 1,927 received hormones, suggesting that fewer than 0.1 percent of all youth in the database received these medications.